Preliminary Results from a Phase IV Surveillance Study of Medical Cannabis Use in Australian Patients With Advanced Cancer Receiving Palliative Care.

Gurgenci, T; Hardy, J; Good, C; Good, P

Preliminary Results from a Phase IV Surveillance Study of Medical Cannabis Use in Australian Patients With Advanced Cancer Receiving Palliative Care.

Gurgenci, T Hardy, J Good, C Good, P

Permalink

Publisher:: MARY ANN LIEBERT, INC
Publication Type:: Journal Article
Citation:: J Palliat Med, 2024, 27, (5), pp. 663-666
Issue Date:: 2024-05

Closed Access

	Filename	Description	Size
	gurgenci-et-al-2024-preliminary-results-from-a-phase-iv-surveillance-study-of-medical-cannabis-use-in-australian.pdf	Published version	112.71 kB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gurgenci, T
dc.contributor.author	Hardy, J
dc.contributor.author	Good, C
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.date.accessioned	2024-11-18T03:04:22Z
dc.date.available	2024-11-18T03:04:22Z
dc.date.issued	2024-05
dc.identifier.citation	J Palliat Med, 2024, 27, (5), pp. 663-666
dc.identifier.issn	1096-6218
dc.identifier.issn	1557-7740
dc.identifier.uri	http://hdl.handle.net/10453/181945
dc.description.abstract	Introduction: Our research group is conducting three large randomized placebo-controlled trials of medicinal cannabis for cancer symptoms. All participants are invited to take part in a posttrial surveillance study. Methods: Participants were given the manufacturers dosing instructions and liberty to titrate to effect. Data were collected on symptoms (Edmonton Symptom Assessment Scale [ESAS] score), perceived benefits, adverse effects, satisfaction with the product, and dose/frequency. Results: Twenty-six percent of eligible participants consented to take part in the surveillance study. Most participants changed their self-titrated dose at least once. Pain, sleep, and mood were the most frequently cited symptoms which improved. Fatigue, nausea, and cognitive impairment were the most frequently mentioned adverse effects. Conclusion: Participants felt confident making changes to their medicinal cannabis dose within the limits suggested by the manufacturer of each product. A number of benefits and adverse effects were ascribed to the product. Benefits were similar to those described in previous studies.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	MARY ANN LIEBERT, INC
dc.relation.ispartof	J Palliat Med
dc.relation.isbasedon	10.1089/jpm.2023.0358
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	Gerontology
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4205 Nursing
dc.subject.mesh	Humans
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Palliative Care
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Neoplasms
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.subject.mesh	Aged
dc.subject.mesh	Adult
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Palliative Care
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Humans
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Palliative Care
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Neoplasms
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.subject.mesh	Aged
dc.subject.mesh	Adult
dc.subject.mesh	Aged, 80 and over
dc.title	Preliminary Results from a Phase IV Surveillance Study of Medical Cannabis Use in Australian Patients With Advanced Cancer Receiving Palliative Care.
dc.type	Journal Article
utslib.citation.volume	27
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-11-18T03:04:20Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	27
utslib.citation.issue	5

Abstract:

Introduction: Our research group is conducting three large randomized placebo-controlled trials of medicinal cannabis for cancer symptoms. All participants are invited to take part in a posttrial surveillance study. Methods: Participants were given the manufacturers dosing instructions and liberty to titrate to effect. Data were collected on symptoms (Edmonton Symptom Assessment Scale [ESAS] score), perceived benefits, adverse effects, satisfaction with the product, and dose/frequency. Results: Twenty-six percent of eligible participants consented to take part in the surveillance study. Most participants changed their self-titrated dose at least once. Pain, sleep, and mood were the most frequently cited symptoms which improved. Fatigue, nausea, and cognitive impairment were the most frequently mentioned adverse effects. Conclusion: Participants felt confident making changes to their medicinal cannabis dose within the limits suggested by the manufacturer of each product. A number of benefits and adverse effects were ascribed to the product. Benefits were similar to those described in previous studies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181945